MCID: VTM033
MIFTS: 47

Vitamin K Deficiency Bleeding

Categories: Blood diseases, Gastrointestinal diseases, Metabolic diseases

Aliases & Classifications for Vitamin K Deficiency Bleeding

MalaCards integrated aliases for Vitamin K Deficiency Bleeding:

Name: Vitamin K Deficiency Bleeding 12 15
Vitamin K Deficiency 12 55 44
Deficiency of Vitamin K 12 33
Vitamin K Deficiency Hemorrhagic Disease 12
Vitamin K 43

Classifications:



External Ids:

Disease Ontology 12 DOID:11249
ICD9CM 35 269.0
MeSH 44 D014813
NCIt 50 C99108
SNOMED-CT 68 52675005
ICD10 33 E56.1
UMLS 72 C0042880

Summaries for Vitamin K Deficiency Bleeding

MedlinePlus : 43 Vitamins are substances that your body needs to grow and develop normally. Vitamin K helps your body by making proteins for healthy bones and tissues. It also makes proteins for blood clotting. If you don't have enough vitamin K, you may bleed too much. Newborns have very little vitamin K. They usually get a shot of vitamin K soon after they are born. If you take blood thinners, you need to be careful about how much vitamin K you get. You also need to be careful about taking vitamin E supplements. Vitamin E can interfere with how vitamin K works in your body. Ask your health care provider for recommendations about these vitamins. There are different types of vitamin K. Most people get vitamin K from plants such as green vegetables, and dark berries. Bacteria in your intestines also produce small amounts of another type of vitamin K.

MalaCards based summary : Vitamin K Deficiency Bleeding, also known as vitamin k deficiency, is related to hereditary combined deficiency of vitamin k-dependent clotting factors and hemophilia b. An important gene associated with Vitamin K Deficiency Bleeding is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Acenocoumarol and Ticagrelor have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and kidney, and related phenotypes are homeostasis/metabolism and mortality/aging

Disease Ontology : 12 A nutritional deficiency disease that is characterized by easy bleeding due to an inability to form blood clots caused by vitamin K deficiency, occurs most commonly in newborns, and has material basis in deficiency of vitamin K secondary to liver prematurity, lack of vitamin K in a breastmillk diet, largely sterile gut, malabsorption, diarrhea, chronic illness, menorrhagia, chronic kidney disease, and some medications.

Wikipedia : 75 Vitamin K deficiency results from insufficient dietary vitamin K1 or vitamin K2 or... more...

Related Diseases for Vitamin K Deficiency Bleeding

Diseases related to Vitamin K Deficiency Bleeding via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 501)
# Related Disease Score Top Affiliating Genes
1 hereditary combined deficiency of vitamin k-dependent clotting factors 33.8 VKORC1 GGCX
2 hemophilia b 32.7 F8 F2
3 protein s deficiency 32.6 PROS1 F2
4 factor vii deficiency 32.6 F8 F2
5 prothrombin deficiency 32.1 GGCX F2
6 hemorrhagic disease 31.0 F8 F2
7 thrombophilia due to thrombin defect 30.8 F8 F2
8 hemophilia 30.6 F8 F2
9 portal vein thrombosis 30.5 F2 AFP
10 cardiac tamponade 30.5 F8 F2
11 purpura 30.5 PROS1 F2
12 esophageal varix 30.5 F2 AFP
13 factor viii deficiency 30.4 F8 F2
14 post-thrombotic syndrome 30.3 F8 F2
15 biliary tract disease 30.2 F2 AFP
16 hemarthrosis 30.2 F8 BGLAP
17 thrombosis 30.1 PROS1 F8 F2
18 blood coagulation disease 30.1 F8 F2
19 retinal vein occlusion 30.1 VKORC1 F2
20 thrombophilia due to activated protein c resistance 30.1 F8 F2
21 thrombophlebitis 30.0 F8 F2
22 retinal vascular occlusion 30.0 VKORC1 F2
23 compartment syndrome 30.0 F8 F2
24 thrombophilia 29.9 PROS1 F8 F2
25 purpura fulminans 29.9 PROS1 F2
26 von willebrand's disease 29.7 F8 F2
27 testicular yolk sac tumor 29.7 F8 AFP
28 viral hepatitis 29.4 F2 AFP
29 pseudoxanthoma elasticum 29.2 VKORC1 MGP GGCX
30 resistance to vitamin k antagonists 12.5
31 hereditary resistance to anti-vitamin k 12.4
32 congenital vitamin k-dependent coagulation factors deficiency 12.4
33 vitamin k antagonists toxicity or dose selection 12.4
34 obsolete: hereditary resistance to anti-vitamin k 12.4
35 vitamin k-dependent clotting factors, combined deficiency of, 1 12.2
36 vitamin k-dependent clotting factors, combined deficiency of, 2 12.2
37 maxillonasal dysplasia, binder type 11.7
38 neonatal adrenoleukodystrophy 11.4
39 factor x deficiency 11.3
40 congenital disorder of glycosylation, type iil 11.3
41 protein c deficiency 11.3
42 galactosemia 11.3
43 cholestasis, progressive familial intrahepatic, 5 11.3
44 atrial fibrillation 10.9
45 cholestasis 10.6
46 pulmonary embolism 10.5
47 vascular disease 10.5
48 biliary atresia 10.4
49 bone resorption disease 10.4
50 liver cirrhosis 10.4

Graphical network of the top 20 diseases related to Vitamin K Deficiency Bleeding:



Diseases related to Vitamin K Deficiency Bleeding

Symptoms & Phenotypes for Vitamin K Deficiency Bleeding

MGI Mouse Phenotypes related to Vitamin K Deficiency Bleeding:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.5 AFP F2 F8 GGCX MGP PROS1
2 mortality/aging MP:0010768 9.17 AFP F2 F8 GGCX MGP PROS1

Drugs & Therapeutics for Vitamin K Deficiency Bleeding

Drugs for Vitamin K Deficiency Bleeding (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
2
Ticagrelor Approved Phase 4 274693-27-5 9871419
3 fluindione Approved, Investigational Phase 4 957-56-2
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
6 Bemiparin Approved, Investigational Phase 4 91449-79-5
7
Ofloxacin Approved Phase 4 82419-36-1 4583
8
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
9
Telithromycin Approved Phase 4 191114-48-4 5462516 70789201
10
Azithromycin Approved Phase 4 83905-01-5 447043 55185
11
Edoxaban Approved Phase 4 480449-70-5
12
Dronedarone Approved Phase 4 141625-93-6, 141626-36-0 154087
13
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
14
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
15
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
16
Dalteparin Approved Phase 4 9005-49-6
17
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
18
Coumarin Experimental Phase 4 91-64-5 323
19 Prasugrel hydrochloride Phase 4 389574-19-0
20 Vitamin MK 7 Phase 4
21 Vitamin K 2 Phase 4
22 Analgesics Phase 4
23 Analgesics, Non-Narcotic Phase 4
24 Peripheral Nervous System Agents Phase 4
25 Antipyretics Phase 4
26 Lipid Regulating Agents Phase 4
27 Hypolipidemic Agents Phase 4
28 Anticholesteremic Agents Phase 4
29 Antimetabolites Phase 4
30 Renal Agents Phase 4
31 Topoisomerase Inhibitors Phase 4
32 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
33 Anti-Infective Agents, Urinary Phase 4
34 Cholestyramine Resin Phase 4
35 polysaccharide-K Phase 4
36 Erythromycin Ethylsuccinate Phase 4
37 Cyclosporins Phase 4
38 Erythromycin stearate Phase 4
39 Erythromycin Estolate Phase 4
40 Fibrinolytic Agents Phase 4
41 Heparin, Low-Molecular-Weight Phase 4
42 calcium heparin Phase 4
43
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
44
Sodium citrate Approved, Investigational Phase 3 68-04-2
45
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
46
Povidone Approved Phase 2, Phase 3 9003-39-8
47
Prilocaine Approved Phase 2, Phase 3 721-50-6 4906
48
Povidone-iodine Approved Phase 2, Phase 3 25655-41-8
49
Thrombin Approved, Investigational Phase 3
50
Protein C Approved Phase 3

Interventional clinical trials:

(show top 50) (show all 479)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
2 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
3 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
4 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
5 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
6 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
7 The Effect of Vitamin K Supplementation on Glucose Metabolism Completed NCT00960973 Phase 4 Menatetrenone;Placebo
8 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
9 The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial Completed NCT02610933 Phase 4 rivaroxaban
10 Multicenter, Prospective Randomized Trial on the Use of Prothrombin Complex and Fresh Frozen Plasma in Patients With Intracerebral Hemorrhage Related to Vitamin K Antagonists Completed NCT00928915 Phase 4 Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
11 An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention Completed NCT02415400 Phase 4 Apixaban;vitamin K antagonist;Acetylsalicylic acid
12 Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY) Completed NCT03091569 Phase 4
13 The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT Completed NCT02376803 Phase 4 Warfarin
14 A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
15 D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized "Prolong" Study Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
16 An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation Completed NCT02227550 Phase 4 Vitamin K antagonist;Apixaban
17 Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism Completed NCT00711308 Phase 4 tinzaparin;acenocoumarol
18 Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis Completed NCT00689520 Phase 4 tinzaparin;acenocoumarol
19 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium Completed NCT02376010 Phase 4 rivaroxaban;Warfarin
20 Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
21 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
22 A Prospective, Randomized Study of Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal at a Large Tertiary Care Medical Center Completed NCT03064035 Phase 4 4-factor prothrombin complex concentrate (4FPCC)
23 the Post Operative Pericardial Effusion (POPE) Treatment Study Completed NCT00247052 Phase 4 diclofenac;diclofenac;matching placebo
24 Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation Completed NCT01339819 Phase 4 Dabigatran;Phenprocoumon
25 An International, Multi-centre, Prospective, Open-Label, Non-Randomised, Uncontrolled Study to Assess the Efficacy and Safety of Prothromplex Total in Oral Anticoagulant Reversal in Patients With Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X) Completed NCT01159210 Phase 4
26 Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants Completed NCT02720328 Phase 4
27 Comparison of the Effect of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes Using the Validated Cooperstown 5+1 Cocktail Completed NCT00164112 Phase 4 Cooperstown 5+1 alone;Azithromycin plus Cooperstown 5+1;Telithromycin plus Cooperstown 5+1;Levofloxacin plus Cooperstown 5+1
28 Reversion of the Anticoagulant Effect of the New Antithrombotic Agents Anti-Xa and Anti IIa by Specific and Non-specific Haemostatic Drugs,: an Ex-Vivo Study in Healthy Volunteers Completed NCT01210755 Phase 4 Rivaroxaban, Dabigatran;Dabigatran; Rivaroxaban
29 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
30 Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study Completed NCT02559856 Phase 4 Apixaban;Rivaroxaban
31 Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
32 EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin Completed NCT01119300 Phase 4
33 EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon Completed NCT01119274 Phase 4
34 EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol Completed NCT01119261 Phase 4
35 Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? Completed NCT02876354 Phase 4 Menaquinone
36 Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study Completed NCT02567461 Phase 4 Edoxaban 60 mg;Edoxaban 30 mg;Clopidogrel 75 mg;Aspirin 81 mg
37 Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study Completed NCT01962545 Phase 4 OAC alone
38 Finding the Optimal Dose of Rivaroxaban in Hemodialysis Patients Completed NCT02047006 Phase 4 Rivaroxaban 10 mg
39 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
40 Randomized Trial of Uninterrupted Versus Interrupted Anticoagulant Therapy in Patients Undergoing Cardiac Pacing Device Implantation Completed NCT00479362 Phase 4 Warfarin;Aspirin
41 A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of Coagulation Activation in Venous and Shed Blood in Healthy Male Subjects Completed NCT01812200 Phase 4 Dabigatran, Ticagrelor, ASA;Rivaroxaban, Ticagrelor, ASA;Phenprocoumon, Ticagrelor, ASA
42 PerMIT: Warfarin : A Prospective Randomized Controlled Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy Completed NCT00993200 Phase 4 Warfarin
43 Absence of Residual Vein Thrombosis After an Episode of Unprovoked Deep Vein Thrombosis: Short-Term Anticoagulation is Safe. Completed NCT00623987 Phase 4 warfarin accordingly INR value
44 Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs Completed NCT00438230 Phase 4 Warfarin
45 Therapeutic Equivalence Between Branded and Generic Warfarin Sodium Tablets in Adult Patients With Atrial Fibrillation in Brazil - Crossover Randomized Controlled Equivalence Trial Completed NCT02017197 Phase 4 Marevan®;generic warfarin #1;generic warfarin #2
46 Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief Completed NCT00286650 Phase 4
47 PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS Completed NCT02249897 Phase 4 CHOLESTYRAMINE
48 Comparison of a Decreasing Dose of Daily Intravenous Vitamin K to a Single Dose Given as Standard of Care to an Historical Cohort in Subjects With Larger Burns Recruiting NCT03941535 Phase 4 Vitamin K
49 A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT Recruiting NCT02464969 Phase 4 Apixaban;Standard of Care
50 Study of the Benefit / Risk Ratio of Oral Anticoagulation in Hemodialysis Patients With Atrial Fibrillation Recruiting NCT02886962 Phase 4 Oral anticoagulation with vitamin K antagonists

Search NIH Clinical Center for Vitamin K Deficiency Bleeding

Cochrane evidence based reviews: vitamin k deficiency

Genetic Tests for Vitamin K Deficiency Bleeding

Anatomical Context for Vitamin K Deficiency Bleeding

MalaCards organs/tissues related to Vitamin K Deficiency Bleeding:

41
Bone, Liver, Kidney, Heart, Testes, Breast, Skin

Publications for Vitamin K Deficiency Bleeding

Articles related to Vitamin K Deficiency Bleeding:

(show top 50) (show all 1078)
# Title Authors PMID Year
1
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. 17
30883055 2019
2
Direct-Acting Oral Anticoagulants and Warfarin-Associated Intracerebral Hemorrhage Protocol Reduces Timing of Door to Correction Interventions. 17
30801446 2019
3
Educating Parents About Vitamin K in the Newborn Using Knowles' Theory of Adult Learning Principles as a Framework. 17
30807347 2019
4
Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging? 9 38
19692494 2009
5
Prevalence of vitamin K and vitamin D deficiency in patients with hepatobiliary and pancreatic disorders. 9 38
19854384 2009
6
Prevalence of subclinical vitamin K deficiency in cholestatic liver disease. 9 38
19502999 2009
7
Coagulation meets calcification: the vitamin K system. 9 38
19363777 2009
8
Extremes in vitamin K status of bone are related to bone ultrasound properties in children with juvenile idiopathic arthritis. 9 38
18578975 2008
9
The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. 9 38
18401181 2008
10
Coagulopathy in liver disease. 9 38
18221607 2007
11
Justifying the clinical use of fresh frozen plasma - an audit. 9 38
17462177 2007
12
Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. 9 38
16807654 2006
13
A case of spontaneous regression of hepatocellular carcinoma with multiple lung metastases. 9 38
16715676 2006
14
Role of vitamin K2 in the treatment of postmenopausal osteoporosis. 9 38
18690918 2006
15
Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. 9 38
16425352 2005
16
Biliary lithiasis in early pregnancy and abnormal development of facial and distal limb bones (Binder syndrome): a possible role for vitamin K deficiency. 9 38
15751048 2005
17
Prevalence and clinical associations of prolonged prothrombin time in adult untreated coeliac disease. 9 38
15075998 2004
18
Effects of vitamin K2 on osteoporosis. 9 38
15320745 2004
19
Echis time, under-carboxylated prothrombin and vitamin K status in intensive care patients. 9 38
14641145 2003
20
Vitamin K and bone health. 9 38
15018483 2003
21
Dietary phylloquinone depletion and repletion in older women. 9 38
12888638 2003
22
Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. 9 38
11994567 2002
23
Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. 9 38
11846334 2001
24
Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. 9 38
11410932 2001
25
Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? 9 38
11247890 2001
26
Vitamin K deficiency in diarrhoea. 9 38
11338219 2001
27
Are breast-fed infants vitamin K deficient? 9 38
11787707 2001
28
Use of oral anticoagulants in older patients. 9 38
10939307 2000
29
Severe acquired vitamin K deficiency: a hypothesis for rapid response to therapy. 9 38
10870812 2000
30
Systemic causes of excessive uterine bleeding. 9 38
10513767 1999
31
Bioavailability of phylloquinone from an intravenous lipid emulsion. 9 38
9537619 1998
32
[How do we manage the hemorrhagic risk on hypovitaminosis K and treatments with antivitamin K]. 9 38
9750673 1998
33
Plasma vitamin K1 level is decreased in primary biliary cirrhosis. 9 38
9362192 1997
34
Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements. 9 38
8989344 1997
35
The effect of combined antenatal vitamin K and phenobarbital therapy on umbilical blood coagulation studies in infants less than 34 weeks' gestation. 9 38
7501353 1995
36
[Intrahepatic cholestasis in pregnancy. The hepatologist's point of view]. 9 38
8228018 1993
37
Vitamin K deficiency. 9 38
7886607 1993
38
Evidence of vitamin K deficiency in cord blood. 9 38
7886551 1993
39
Hemolytic uremic syndrome complicated by vitamin K deficiency. 9 38
2069228 1991
40
Prediction of vitamin K response using the Echis time and Echis-prothrombin time ratio. 9 38
2096486 1990
41
Chemical modification of gamma-carboxyglutamic acid residues in prothrombin elicits a conformation similar to that of abnormal (des-gamma-carboxy)prothrombin. 9 38
2277030 1990
42
Factor VII deficiency - an enigma; clinicohematological profile in 12 cases. 38
30191763 2019
43
Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis. 38
31119401 2019
44
Acquired Factor VII deficiency - a rare but important consideration. 38
31142211 2019
45
Spontaneous intracranial haemorrhage in children-intensive care needs and predictors of in-hospital mortality: a 10-year single-centre experience. 38
31165253 2019
46
Increasing the dose of oral vitamin K prophylaxis and its effect on bleeding risk. 38
31062090 2019
47
Trends of INR and Fecal Excretion of Vitamin K During Cholestasis Reversal: Implications in the Treatment of Neonates With Intestinal Failure-Associated Liver Disease. 38
31282035 2019
48
Diversity of Gut Microbiota Affecting Serum Level of Undercarboxylated Osteocalcin in Patients with Crohn's Disease. 38
31288415 2019
49
Prophylactic Vitamin K Administration in Neonates on Prolonged Antibiotic Therapy: A Randomized Controlled Trial. 38
31278224 2019
50
Quantitation of vitamin K1 in serum using online SPE-LC-MS/MS and the challenges of working with vitamin K. 38
30995590 2019

Variations for Vitamin K Deficiency Bleeding

Expression for Vitamin K Deficiency Bleeding

Search GEO for disease gene expression data for Vitamin K Deficiency Bleeding.

Pathways for Vitamin K Deficiency Bleeding

Pathways related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.63 PROS1 F8 F2
2 11.47 PROS1 F8 F2
3 11.35 BGLAP AFP
4
Show member pathways
11.29 PROS1 GGCX F2 BGLAP
5 11.05 F2 AFP
6 10.9 MGP BGLAP
7
Show member pathways
10.68 VKORC1 GGCX
8 10.28 VKORC1 PROS1 MGP GGCX F2 BGLAP

GO Terms for Vitamin K Deficiency Bleeding

Cellular components related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 PROS1 F8 F2 BGLAP AFP
2 extracellular region GO:0005576 9.63 PROS1 MGP F8 F2 BGLAP AFP
3 platelet alpha granule lumen GO:0031093 9.32 PROS1 F8
4 Golgi lumen GO:0005796 9.13 PROS1 F2 BGLAP
5 endoplasmic reticulum lumen GO:0005788 8.92 F8 F2 BGLAP AFP

Biological processes related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bone development GO:0060348 9.48 VKORC1 BGLAP
2 acute-phase response GO:0006953 9.46 F8 F2
3 regulation of bone mineralization GO:0030500 9.43 MGP BGLAP
4 hemostasis GO:0007599 9.43 PROS1 F8 F2
5 fibrinolysis GO:0042730 9.4 PROS1 F2
6 blood coagulation, intrinsic pathway GO:0007597 9.37 F8 F2
7 regulation of blood coagulation GO:0030193 9.32 VKORC1 F2
8 ER to Golgi vesicle-mediated transport GO:0006888 9.26 PROS1 F8 F2 BGLAP
9 peptidyl-glutamic acid carboxylation GO:0017187 9.16 VKORC1 GGCX
10 blood coagulation GO:0007596 9.02 VKORC1 PROS1 GGCX F8 F2

Molecular functions related to Vitamin K Deficiency Bleeding according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.26 PROS1 MGP F2 BGLAP
2 structural constituent of bone GO:0008147 8.62 MGP BGLAP

Sources for Vitamin K Deficiency Bleeding

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....